Robert Fox, MD
Neuroimmunology
Highlights
Age Groups Seen
- Adult
Languages
- English
Gender
MaleAbout Robert Fox
Biography
He serves as an advisory committee member and principal site investigator for many clinical trials, including coordinating global principal investigator for a Phase III clinical trial of dimethyl fumarate in relapsing remitting multiple sclerosis (MS).
Dr. Fox's current research interests focus on innovative MRI techniques to evaluate MS treatments and tissue recovery after injury, where he is principal investigator and co-investigator on grants funded by the NIH and National MS Society. He serves as a member of various advisory and review committees for the National MS Society. He is also Managing Director of the NARCOMS MS Patient Registry, a member of the General Advisory Council and Research Programs Committee for the Cleveland Clinic General Clinical Research Center, and a consultant to the pharmaceutical industry regarding the development of new treatments for MS.
Request Second Opinion
Get the peace of mind you deserve. When it matters most, you can count on a second opinion from the experts at Cleveland Clinic. Find answers. Feel confident. Get a Second Opinion.
Locations
- U Building - Mellen Center
- 1950 East 89th Street, Cleveland, OH 44106
- Get Directions
- U Building - Mellen Center
- 1950 East 89th Street, Cleveland, OH 44106
- Get Directions
Education & Board Certifications
Education
- Graduate School: Case Western Reserve University School of Medicine, 2003
- Fellowship: Cleveland Clinic, 2002
- Residency: Hospital of The University of Pennsylvania, 2000
- Internship: Hospital of The University of Pennsylvania, 1997
- Medical Education: Johns Hopkins University School of Medicine, 1996
- Undergraduate: Amherst College, 1991
Board Certifications
- Neurology: American Board of Psychiatry & Neurology, 2001
Professional Highlights
- Advisory Committee on Fellowships, National Multiple Sclerosis Society (Chair, 2011-2012)
- International Coordinating Investigator, Phase III clinical trial of BG00012
- Editorial Board, Neurology and Multiple Sclerosis Journal
- Managing Director, NARCOMS MS Patient Registry
- Scientific Expert Working Group on CCSVI, Canadian Institutes of Health Research
- MS Clinical Phenotype Subcommittee, International Advisory Committee on Clinical Trials in MS
- Medical Monitor, Phase I Study of Mesenchymal Stem Cell Transplantation in MS
- Ad hoc reviewer, NIH ZRG1 BDCN-N Member Conflict Special Emphasis Panel
- Committee for Responsible Research Conduct, Cleveland Clinic
- Neurosciences Sub-Chair, Research Programs Committee, Cleveland Clinic
Additional Training
- Masters of Science in Clinical Research, Case Western Reserve University, 2003
Awards
- 1991 James Olds Memorial Neuroscience Thesis Award
- 1992 Alpha Omega Alpha Honor Society Grant
- 1996 Sellards Travel Award to Johannesburg, South Africa
- 1996 Medical and Chirurgical Society of Maryland Award for Excellence in Organized Medicine
- 1996 Harold Lamport Biomedical Research Prize, Johns Hopkins University
- 1999 Zeritzky Resident Clinical Research Award, University of Pennsylvania
- 2000 Potiker Fellow, Mellen Center for Multiple Sclerosis Treatment and Research
- 2001 National Multiple Sclerosis Society Dale McFarlin Travel Award
- 2003-2012 Top Doctors, Cleveland Magazine
- 2008 Outstanding Physician/PA Team, Cleveland Clinic
- 2009 Fellow, American Academy of Neurology
- 2011 Researcher Hall of Fame, National MS Society
Professional Memberships
Research & Publications
See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.
As of 2025-12-08, Dr. Fox has reported the financial relationships with the companies listed below.
Consulting and/or Speaking. Dr. Fox receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:
- Roche (Hoffman-La Roche, Ltd.)
- Sudo Biosciences, Inc.
- Sanofi Genzyme
- Roche Diagnostics Corporation
- Immunic, Inc.
- Population Council, Inc.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.